Verastem | VSTM - Operating Profit

Stock Price
5.91
Daily Change
-0.61 -9.36%
Monthly
9.65%
Yearly
-16.05%
Q2 Forecast
6.44

Verastem reported $-41.48M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alaunos Therapeutics USD -1.19M 148K Sep/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Curis USD -7.88M 4.63M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Laboratory Of America USD 382M 15.3M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -41.48M 23.2M Dec/2025